Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 167 of 6351
-
Can an immunotherapy drug outsmart a returning brain tumor?
Disease control OngoingThis phase II trial studies the effects of pembrolizumab on the body, or pharmacodynamics, in patients with glioblastoma that has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere wit…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can trained immune cells stop blood cancer relapse?
Disease control Recruiting nowThis Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Phase 1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
HIV heart risk: statin pill could save lives
Prevention CompletedPeople with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols: * REPRIEVE (A5332) was fund…
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 26, 2026 13:58 UTC
-
New drug combo shows promise for advanced breast cancer in asian women
Disease control CompletedThe study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to beat High-Risk hodgkin lymphoma in kids
Disease control OngoingThis phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug cocktail shows promise against Drug-Resistant TB
Disease control CompletedThe purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of bedaquiline plus PA-824 plus linezolid after 6 months of treatment (option for 9 months for participants who remain culture positive at month 4) in participants with either pulmona…
Phase 3 • Sponsor: Global Alliance for TB Drug Development • Aim: Disease control
Last updated Jun 26, 2026 14:29 UTC
-
Could dropping one chemo drug improve life for young brain tumor patients?
Disease control CompletedThis study is trying to learn and understand if the chemotherapy drug called carboplatin works as well as the standard therapy. The standard therapy for Low Grade Glioma (LGG) in children and young adults is using a combination of carboplatin and vincristine. Studies in children …
Phase 3 • Sponsor: Alicia Lenzen • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for Drug-Resistant HIV: fostemsavir shows promise in Late-Stage trial
Disease control OngoingThe purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Phase 3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug cocktail shows promise in slowing blood cancer progression
Disease control CompletedThe purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of pl…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Targeted pill may keep EGFR lung cancer from returning after surgery
Disease control OngoingThis phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (resected). Erlotinib hydrochloride may stop the growth of tumor ce…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
A new heart valve without open surgery? a trial puts it to the test
Disease control CompletedThe purpose of this study is to evaluate the safety and initial performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.
Sponsor: Shockwave Medical, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can early HIV treatment free infants from lifelong meds?
Disease control Recruiting nowThe study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
Can a Marine-Derived drug slow advanced soft tissue sarcoma?
Disease control CompletedAs the transparency committee of the Haute Autorité de Santé pointed out due to lack of data regarding comparative trial of Yondelis versus best supportive care, activity of Yondelis in soft tissue sarcoma remain to be assessed. For an antineoplastic drug toxicity is moderate. A…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a bone drug extend life in advanced lung cancer?
Disease control Stopped earlyThe purpose of this study is to investigate how well the standard treatment (platinum-based doublet chemotherapy) in combination with denosumab works compared with the standard treatment alone in patients with a type of lung cancer called "non small cell lung cancer" (NSCLC) that…
Phase 3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a shorter, stronger radiation course beat standard therapy for High-Risk prostate cancer?
Cure OngoingIn North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients. This phase III clinical trial is designed to compare the safety of a sta…
Phase 3 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo shows promise for leukemia patients with other health problems
Disease control CompletedThis open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical condition…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise in delaying prostate cancer spread
Disease control OngoingThe purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both. The randomized / blinded portion of the study is now completed following primary endpoint…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a smart immune therapy beat chemo for relapsed childhood leukemia?
Disease control OngoingThis randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab may allow …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Promising combo targets deadliest brain tumors
Disease control OngoingThis randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tum…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedBackground: \- One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells. Objective: \- To see if givin…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC